Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
Authors
Keywords
-
Journal
SEMINARS IN LIVER DISEASE
Volume -, Issue -, Pages -
Publisher
Georg Thieme Verlag KG
Online
2021-07-22
DOI
10.1055/s-0041-1731707
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results
- (2020) K.J. Lucas et al. DIGESTIVE AND LIVER DISEASE
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Bile Acid Sequestration Reverses Liver Injury and Prevents Progression of NASH in Western Diet-Fed Mice
- (2020) Shogo Takahashi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Absence of Bsep/Abcb11 attenuates MCD‐diet induced hepatic steatosis but aggravates inflammation in mice
- (2020) Claudia Daniela Fuchs et al. LIVER INTERNATIONAL
- SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
- (2020) Jiyu Zhou et al. Nature Communications
- Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
- (2020) Svenja Sydor et al. Clinical and Translational Gastroenterology
- Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
- (2020) Philip N. Newsome et al. JOURNAL OF HEPATOLOGY
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells
- (2020) Clarissa Campbell et al. NATURE
- Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
- (2020) Zobair M. Younossi et al. Clinical Gastroenterology and Hepatology
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
- (2020) Stephen A. Harrison et al. GASTROENTEROLOGY
- Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders
- (2020) Saul J. Karpen et al. Hepatology International
- Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet
- (2020) Kazuya Okushin et al. PLoS One
- Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis
- (2020) Yuki Tsuji et al. Microorganisms
- Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
- (2020) Alessandro Mantovani et al. GUT
- The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in Nonalcoholic Steatohepatitis
- (2020) Rohit Loomba et al. HEPATOLOGY
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- (2020) Rohit Loomba et al. HEPATOLOGY
- Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study
- (2019) Richard N. Appleby et al. PLoS One
- NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
- (2019) Stephen A. Harrison et al. HEPATOLOGY
- Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism
- (2019) Jonathan Scheiman et al. NATURE MEDICINE
- Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
- (2019) Stefan Traussnigg et al. Lancet Gastroenterology & Hepatology
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression
- (2019) Fabián Segovia-Miranda et al. NATURE MEDICINE
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
- (2019) Michael K. Badman et al. Clinical Pharmacology in Drug Development
- Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
- (2018) Juan Pablo Arab et al. Annual Review of Pathology-Mechanisms of Disease
- Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease
- (2018) Weijun Wang et al. BRITISH JOURNAL OF PHARMACOLOGY
- Update on FXR Biology: Promising Therapeutic Target?
- (2018) Chang Han INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis
- (2018) Anika L. Dzierlenga et al. JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
- Lipotoxicity and the gut-liver axis in NASH pathogenesis
- (2018) Fabio Marra et al. JOURNAL OF HEPATOLOGY
- FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver
- (2018) Romeo Papazyan et al. JOURNAL OF LIPID RESEARCH
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries
- (2018) Magnus Holmer et al. LIVER INTERNATIONAL
- INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis
- (2018) Jonathan D Roth et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
- (2018) Toshihiro Goto et al. Scientific Reports
- Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- (2018) Zobair Younossi et al. HEPATOLOGY
- Ductular reaction in liver diseases: pathological mechanisms and translational significances
- (2018) Keisaku Sato et al. HEPATOLOGY
- Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
- (2018) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial
- (2018) Gideon M. Hirschfield et al. JOURNAL OF HEPATOLOGY
- Non-alcoholic fatty liver disease – A global public health perspective
- (2018) Zobair M. Younossi JOURNAL OF HEPATOLOGY
- Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis
- (2018) Raffaella Maria Gadaleta et al. Scientific Reports
- Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome
- (2018) Maja Ðanić et al. Frontiers in Pharmacology
- Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation
- (2017) David Goldberg et al. GASTROENTEROLOGY
- Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
- (2017) Oscar Chávez-Talavera et al. GASTROENTEROLOGY
- Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
- (2017) Leon A Adams et al. GUT
- Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD
- (2017) Na Jiao et al. GUT
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- New therapeutic concepts in bile acid transport and signaling for management of cholestasis
- (2017) Michael Trauner et al. HEPATOLOGY
- The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids
- (2017) Puneet Puri et al. HEPATOLOGY
- The ascending pathophysiology of cholestatic liver disease
- (2017) Peter L.M. Jansen et al. HEPATOLOGY
- Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects
- (2017) Vanessa Legry et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment
- (2017) Vincent Wai-Sun Wong et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Targeting hepatic macrophages to treat liver diseases
- (2017) Frank Tacke JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
- (2017) Gideon M. Hirschfield et al. JOURNAL OF HEPATOLOGY
- The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
- (2017) Philipp Schwabl et al. JOURNAL OF HEPATOLOGY
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD
- (2017) Valerio Nobili et al. LIVER INTERNATIONAL
- Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
- (2017) Wei Jia et al. Nature Reviews Gastroenterology & Hepatology
- The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
- (2017) Sophie Cazanave et al. Scientific Reports
- An Intestinal Farnesoid X Receptor–Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice
- (2016) Cen Xie et al. DIABETES
- An Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease
- (2016) Frank J. Gonzalez et al. GASTROENTEROLOGY
- Microbiota-induced obesity requires farnesoid X receptor
- (2016) Ava Parséus et al. GUT
- Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
- (2016) Juan P. Arab et al. HEPATOLOGY
- Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis
- (2016) Benjamin Lelouvier et al. HEPATOLOGY
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet–fed mice
- (2016) Anuradha Rao et al. Science Translational Medicine
- Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease
- (2016) Claudia Fuchs et al. SEMINARS IN LIVER DISEASE
- FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
- (2016) Len Verbeke et al. Scientific Reports
- Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease
- (2016) Marialena Mouzaki et al. PLoS One
- The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats
- (2015) Len Verbeke et al. AMERICAN JOURNAL OF PATHOLOGY
- Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis
- (2015) Brian C. Ferslew et al. DIGESTIVE DISEASES AND SCIENCES
- Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
- (2015) Robert J. Wong et al. GASTROENTEROLOGY
- Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice
- (2015) Zhibo Gai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
- (2015) Michaela Mueller et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
- (2015) Sungsoon Fang et al. NATURE MEDICINE
- Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander
- (2015) Ester Vanni et al. SEMINARS IN LIVER DISEASE
- Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease
- (2015) Sanjaya Satapathy et al. SEMINARS IN LIVER DISEASE
- Nonalcoholic fatty liver disease
- (2015) Elizabeth M. Brunt et al. Nature Reviews Disease Primers
- Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
- (2014) M. Zhou et al. CANCER RESEARCH
- Nuclear bile acid signaling through the farnesoid X receptor
- (2014) Claire Mazuy et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Bile acids and the gut microbiome
- (2014) Jason M. Ridlon et al. CURRENT OPINION IN GASTROENTEROLOGY
- Saturated free fatty acids induce cholangiocyte lipoapoptosis
- (2014) Sathish Kumar Natarajan et al. HEPATOLOGY
- Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
- (2014) Changtao Jiang et al. JOURNAL OF CLINICAL INVESTIGATION
- Bile acid receptors in non-alcoholic fatty liver disease
- (2013) Yuanyuan Li et al. BIOCHEMICAL PHARMACOLOGY
- Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist
- (2013) Sama I. Sayin et al. Cell Metabolism
- Human Insulin Resistance Is Associated With Increased Plasma Levels of 12 -Hydroxylated Bile Acids
- (2013) R. A. Haeusler et al. DIABETES
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis
- (2013) Lars P. Bechmann et al. HEPATOLOGY
- Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
- (2013) Len Verbeke et al. HEPATOLOGY
- Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease
- (2013) Rachel H. McMahan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
- (2013) Shin Yoshimoto et al. NATURE
- Bile acid receptors as targets for drug development
- (2013) Frank G. Schaap et al. Nature Reviews Gastroenterology & Hepatology
- Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease
- (2013) Anna Alisi et al. PLoS One
- Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
- (2013) V. K. Ridaura et al. SCIENCE
- Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity
- (2013) Fei Li et al. Nature Communications
- Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice
- (2012) Matthew J. Potthoff et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances Cyclin D1 expression and promotes human endometrial cancer cell proliferation
- (2012) Ivan Casaburi et al. CELL CYCLE
- Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease
- (2012) Hae-Ki Min et al. Cell Metabolism
- Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease
- (2012) Fatih Eren et al. CLINICAL BIOCHEMISTRY
- Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial
- (2012) Thuy-Anh Le et al. HEPATOLOGY
- Abcb11Deficiency Induces Cholestasis Coupled to Impaired β-Fatty Acid Oxidation in Mice
- (2012) Yuanyuan Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Role of ceramides in nonalcoholic fatty liver disease
- (2012) Mangesh Pagadala et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Bile Acids Induce Inflammatory Genes in Hepatocytes
- (2011) Katryn Allen et al. AMERICAN JOURNAL OF PATHOLOGY
- FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway
- (2011) Matthew J. Potthoff et al. Cell Metabolism
- Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis
- (2011) Srinivasan Dasarathy et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
- (2011) R. M. Gadaleta et al. GUT
- Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes
- (2011) Elaine Studer et al. HEPATOLOGY
- Ursodeoxycholic acid dose-dependently improves liver injury in rats fed a methionine- and choline-deficient diet
- (2011) Vyacheslav U. Buko et al. HEPATOLOGY RESEARCH
- The G Protein-Coupled Bile Acid Receptor, TGR5, Stimulates Gallbladder Filling
- (2011) Tingting Li et al. MOLECULAR ENDOCRINOLOGY
- FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
- (2011) S. Kir et al. SCIENCE
- The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance
- (2010) Tim C. M. A. Schreuder et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Bile Acid Sequestrants for Lipid and Glucose Control
- (2010) Bart Staels et al. Current Diabetes Reports
- Tauroursodeoxycholic Acid May Improve Liver and Muscle but Not Adipose Tissue Insulin Sensitivity in Obese Men and Women
- (2010) Marleen Kars et al. DIABETES
- Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis
- (2010) N. Beraza et al. GUT
- High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial
- (2010) Ulrich F. H. Leuschner et al. HEPATOLOGY
- The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation
- (2010) Thijs W.H. Pols et al. JOURNAL OF HEPATOLOGY
- A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
- (2010) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Plasma metabolomic profile in nonalcoholic fatty liver disease
- (2010) Satish C. Kalhan et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts
- (2009) Peter Fickert et al. AMERICAN JOURNAL OF PATHOLOGY
- TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
- (2009) Charles Thomas et al. Cell Metabolism
- Bile acid levels are increased in the liver of patients with steatohepatitis
- (2009) Márcia M. Aranha et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- The enterohepatic circulation of bile acids in mammals: form and functions
- (2009) Alan et al. Frontiers in Bioscience-Landmark
- Quality of life in adults with nonalcoholic fatty liver disease: Baseline data from the nonalcoholic steatohepatitis clinical research network
- (2009) Kristin David et al. HEPATOLOGY
- The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders
- (2009) Verena Keitel et al. HEPATOLOGY
- Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
- (2009) Songwen Zhang et al. JOURNAL OF HEPATOLOGY
- Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/−and apoE−/−mice
- (2009) Helen B. Hartman et al. JOURNAL OF LIPID RESEARCH
- FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
- (2009) Sabrina Cipriani et al. JOURNAL OF LIPID RESEARCH
- Common Variants of ABCB4 and ABCB11 and Plasma Lipid Levels: A Study in Sib Pairs with Gallstones, and Controls
- (2009) Monica Acalovschi et al. LIPIDS
- The common bile salt export pump (ABCB11) p.A444V variant is associated with BMI levels in the general population
- (2009) M Krawczyk et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y12 purinergic receptors
- (2008) Anatoliy I. Masyuk et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Antiatherosclerotic effect of farnesoid X receptor
- (2008) Andrea Mencarelli et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance
- (2008) J L Newton et al. GUT
- Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression
- (2008) Kwang-Hoon Song et al. HEPATOLOGY
- High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis
- (2008) Frank G. Schaap et al. HEPATOLOGY
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
- (2008) Yan-Dong Wang et al. HEPATOLOGY
- 98 DIFFERENTIAL EFFECTS OF NORUDCA AND UDCA IN THE TREATMENT OF FATTY LIVER AND ARTERIOSCLEROSIS IN WESTERN CHOW-FED APOE KNOCK OUT MICE
- (2008) P. Fickert et al. JOURNAL OF HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More